STAMPEDE (clinical trial)

STAMPEDE is an acronym for "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy".

[1] The trial investigates new approaches for men with metastatic and locally advanced prostate cancer.

[1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial.

Standard of care (SOC) is lifelong androgen deprivation therapy (ADT).

They also noted that docetaxel plus zoledronic acid "was associated with similar improvements, although the benefit observed was smaller".

Differences between healthy prostate and a prostate with a tumour